ABSTRACT: A quinazolinedione-derived screening hit 2 was discovered with cellular antiviral activity against respiratory syncytial virus (CPE EC 50 = 2.1 μM), moderate efficacy in reducing viral progeny (4.2 log at 10 μM), and marginal cytotoxic liability (selectivity index, SI ∼ 24). Scaffold optimization delivered analogs with improved potency and selectivity profiles. Most notable were compounds 15 and 19 (EC 50 = 300−500 nM, CC 50 > 50 μM, SI > 100), which significantly reduced viral titer (>400,000-fold), and several analogs were shown to block the activity of the RNA-dependent RNA-polymerase complex of RSV.
■ INTRODUCTION
Acute bronchiolitis, a common lower respiratory tract infection most seriously affecting infants and the elderly, is predominately caused by the highly infectious human respiratory syncytial virus (hRSV). 1−4 The virus belongs to the paramyxovirus family, which also includes mumps and measles viruses; 5 however, unlike these related pathogens for which vaccines have been developed, a safe and effective vaccine remains elusive to prevent the contraction and transmission of RSV. 6, 7 In fact, since the discovery 8 of the virus over 50 years ago, the only FDA approved small molecule inhibitor for treatment of the infection is ribavirin, a nucleoside antimetabolite, that is limited to use in critical cases due to its toxicological side effects. 9, 10 In the United States, the prevalence of RSV infection in adults over the age of 65 results in approximately 170,000 hospitalizations and 10,000 deaths annually 11 while the global incidence of RSV infection was estimated in 2005 to result in the hospitalization of 3.4 million children under the age of 5. 12 Furthermore, exposure does not impart full immunity from future infection and, in fact, promotes an inflammatory response that can contribute to chronic lung complications such as asthma. 13, 14 These burdens, coupled with the absence of suitable therapeutic agents for susceptible populations, underscore the importance of identifying effective and safe pharmacological countermeasures for RSV.
The scientific literature is replete with examples from translational development programs aimed at addressing this important need. 15−17 Replication inhibitors 18−22 have been investigated, along with several compounds that target RSV's entry-enabling F protein, 23−27 though in most cases the compounds were not pursued or clinical development was discontinued. 28, 29 Despite these efforts, the search continues for RSV inhibitors that offer a superior pharmacological and safety profile compared to that of ribavirin.
30
As part of the National Institutes of Health Molecular Libraries Initiative, we pursued a subset of RSV-inhibiting hit scaffolds identified through a high-throughput screen 31−33 of the national compound repository. 34 Optimization of a screening hit led to compound 1, probe ML232, a sulfonamide-based RSV inhibitor with single-digit micromolar in vitro activity, and a proposed entry-based mechanism of inhibition based on time-of-addition studies ( Figure 1A) . 15, 35 In a parallel effort, the team also launched an optimization campaign on a quinazolinedione compound series for which we noted key differences with respect to the breadth of tunable structure−activity and structure−property relationships (SAR and SPR, respectively) and a potentially different mechanism of action as compared to the ML232 compound series. The quinazolinedione hit 2 was determined to inhibit a RSVinduced cytopathic effect with an EC 50 of 2.14 μM and showed HEp-2 cellular toxicity with a CC 50 > 50 μM, resulting in a selectivity index (CC 50 /EC 50 ) of >23.8 ( Figure 1B ). In a titer reduction assay, hit 2 was also found to reduce viral plaques by 4.2 log (∼14,000-fold as compared to control) at a concentration of 10 μM. The team undertook an optimization effort that focused on the five colored regions of the scaffold with the primary aims of broadening the selectivity index by enhancing potency and attenuating cellular toxicity, amplifying the plaque reducing effect, and improving solubility ( Figure  1B ).
■ CHEMISTRY
Analogs of hit 2 were generally prepared using standard peptide coupling conditions of 2-amino benzoic acid 3 with methyl 4-(aminomethyl)benzoate to afford an aminobenzamide intermediate (Scheme 1). Subsequent cyclization with CDI generated quinazolinedione core intermediate 4. Most analogs were made by ester hydrolysis of 4, followed by incorporation of the pendent amido alkyl ether (R 2 ) with routine amide coupling, followed by installation of the N-benzyl appendage (R 1 ) to afford products 5. In some cases, it was advantageous to affix the N-benzyl portion prior to revealing the benzoic acid functionality for coupling to the preferred amine component (i.e., shuffling the sequence of R 1 vs R 2 integration). In either case, the synthetic route was flexible and offered selective, orthogonal, late-stage diversification to prepare the desired analog sets. Quinazolinones 7 were also prepared from anthranillic acid 3. Amide coupling between 3 and methyl 4-(aminomethyl)benzoate afforded a 2-aminobenzamide intermediate that was treated with an isopropylphenylacetic acid chloride. The resulting bis-amide 6 was treated with hydroxide base to reveal a benzoic acid that could be further manipulated; however, these conditions fortuitously induced the intended hydrolysis and necessary cyclization to generate the quinazolinone core in one step. Subsequent coupling of the unmasked benzoic acid with 3-methoxypropylamine afforded the desired analogs 7.
■ RESULTS AND DISCUSSION
Medicinal Chemistry Optimization. For this stage of our program, 73 quinazolinedione-derived analogs were prepared and analyzed. All compounds were evaluated for inhibition of an RSV-induced cytopathic effect and assessment of mammalian cell cytotoxicity. Both assays were performed in a 10-point dose response format using HEp-2 cells (hRSV strain Long), and the data from these screens was employed to drive iterative structural revision. A smaller subset of the most promising analogs was subsequently tested for their ability to reduce viral plaques at a compound concentration of 10 μM. Solubility was determined for selected analogs as their overall activity profiles were improved and as modifications were implemented with an expectation of enhancing this particular parameter.
Initially, changes in the quinazolinedione N-benzyl entity (R 1 ) were examined while preserving the hit structure's 3-methoxypropylamine (R 2 ) component (Table 1) . Replacement of the 4-methylbenzyl substituent with a hydrogen atom or use of truncated alkyl replacements such as N-methyl, N-n-propyl, or N-CH 2 -cyclohexyl were not tolerated, resulting in a loss of potency (EC 50 > 50 μM). Similarly, extension of the R 1 benzyl linker by one additional methylene unit was not advantageous (N-(CH 2 ) 2 -4-tolyl, or N-(CH 2 ) 2 -4-trifluoromethylphenyl, or N-(CH 2 ) 2 -4-bromophenyl, EC 50 > 50 μM). Generally, 4-benzyl substitution was preferred, as 3-substituted benzyl derivatives lost potency compared to hit 2, and 2-substituted benzyl analogs were inactive (Table 1) . Increasing steric bulk at the 4-benzyl position (methyl (2) → ethyl (18) → i-propyl (19)) resulted in improved potency. Importantly, cell toxicity was not observed at concentrations exceeding 50 μM for these analogs. Electron withdrawing groups incorporated at this same position were acceptable, and those that mimicked the steric character of small branched aliphatic groups already known to be beneficial were the most promising. Consequently, the N-4-nitrobenzyl derivative 15 and the N-4-isopropylbenzyl analog 19 showed the best potency, viral titer assay efficacy, and cytotoxicity profile in the collection. Heterocyclic variants in this region led to suboptimal potency, cytotoxicity, and reduction in viral plaques (entries 14−17).
Alterations of the secondary amide (R 2 ) were independently carried out in a parallel effort. Exchange of the methyl ether for the ethyl or isopropyl ether did not appreciably alter potency in the CPE assay; however, the cytotoxic effects associated with those analogs increased relative to the parent hit 2 ( Table 2 , entries 1−3). Replacement of the methyl ether with a tertiary amine for the purpose of enhancing solubility was inferior in terms of both potency and toxicity (entry 4). Elongation of the alkyl chain by one methylene unit only marginally enhanced potency and reduced the therapeutic window (entry 5); however, truncating the linker afforded analog 28 with comparable potency to hit 2 (entry 6). Introducing an oxetane as a cyclized version of the linear ether chain resulted in a promising potency, cytotoxicity, and viral plaque reduction profile (entry 7). Other modifications were explored to improve solubility or potency without inducing cytotoxicity, but none were found to be more advantageous when considering multiparameter optimization.
Hybrid analogs derived from the most advantageous individual R 1 or R 2 modifications were then prepared to assess synergistic effects, and additional SAR data was pursued using these compounds as templates. At this stage, several compounds were also evaluated for improvement in solubility. The initial analog sets (Tables 1 and 2 ) revealed that analogs bearing the 4-isopropylbenzyl or 4-nitrobenzyl moiety for R 1 and the R 2 modification of a NHCH 2 -3-oxetane were independently the most beneficial in terms of combined potency, cytotoxicity, and plaque reduction (compounds 15, 19, and 29, respectively). In pairing the 4-nitrobenzyl functionality (R 1 ) with the NHCH 2 -3-oxetane (R 2 ) subunit, compound 43 (entry 2, Table 3 ) showed comparable potency and toxicity to hit 2, but with a 14-fold improvement in PBS solubility and at least a 2 log increase in capacity to reduce viral titer. Combining the 4-isopropylbenzyl group (R 1 ) with the NHCH 2 -3-oxetane (R 2 ) component resulted in potency comparable to the best analogs in the series (44, entry 3, Table 3 ); however, the selectivity index was diminished due to unwanted cytotoxicity. Alternatives to the 4-nitrobenzyl element were examined, such as a 4-benzoic acid derivative 45 which imparted a desirable solubility effect but also abrogated activity, which may be the result of reduced cellular permeability. The N-4-dimethylaminobenzyl analog 46 was also found to have improved solubility but did not robustly provide cytoprotection to the extent observed with other architectural combinations (entry 5). Furyl and pyridyl variants in place of the R 2 appendage were also determined to be suboptimal overall (entries 7−9 and other analogs not shown). Analogs bearing a substituent (halide, −OCH 3 , −CH 3 , or −CF 3 ) at the C6 or C7 position of the quinazolinedione core resulted in loss of potency (EC 50 > 50 μM). The same result was determined for analogs with an extra methylene spacer between the core and the benzamide moiety or for compounds with the metapositioned amide functionality as opposed to the paraarrangement present in the hit (data not shown).
Given the idiosyncractic cytotoxicity profile for several of the compounds in the quinazolinedione series and our experience with a related, antiviral quinazolinone scaffold 36, 37 that lacked any detectable mammalian cytotoxicity, two quinazolinone analogs were prepared to explore if this modified core was beneficial against RSV (51−52, Figure 2 ). Quinazolinone analogs 51 and 52 were generated bearing peripheral components that had been shown to possess anti-RSV activity when integrated with the quinazolinedione core. While the compounds were not protective against RSV (>50 μM), the effort underscored the importance of the carbonyl group situated between the core nitrogens to retaining anti-RSV potency. Additionally, the impact of introducing a nitrogen atom into the fused phenyl ring of the quinazolinedione core was studied (53−54, Figure 2 ). Only analog 54 was weakly active, but the compound also demonstrated some appreciable toxicity. Though limited somewhat in scope, the core alterations represented by these four analogs and those previously discussed in which functional groups were introduced at the C6 or C7 position of the scaffold showed that no core modification made to date was well tolerated.
Profiling Assays. The purpose of this program was to identify and develop new compounds with compelling in vitro anti-RSV activity that could be used as a platform for deriving suitable probes for future in vivo efficacy studies. Toward this goal, several analogs emerged from the SAR effort as interesting probe candidates worthy of further characterization based on improvements in CPE potency, solubility, and viral titer. Nonetheless, limitations in aqueous solubility or the presence of functionality with suspected metabolic liability prompted the team to assess passive permeability and hepatocyte toxicity for (Table 4) .
Aqueous solubility for isopropylbenzyl derivative 19 was the most limited of these three compounds, resulting in a skewed result in aqueous stability (27% parent remaining, entry 2, Table 4 ). The addition of acetonitrile to the stability experiment to account for compound precipitation in PBS alone reflected that compound 19 was stable to degradation. Solubility for each compound in CPE assay media was improved compared to PBS buffer, likely due to protein binding. Passive permeability was negligible for 19 in PBS, as expected from the solubility data. Moderate to good permeability was observed for the nitrobenzyl and oxetanecontaining derivatives 15 and 46, respectively, at each of 3 pH levels. Toxicity in hepatocytes, most concerning for the nitrobenzyl analog 15, was not observed (>50 μM), nor was it significant with the other two analogs tested. While each compound possessed desirable attributes, compound 19 was selected as our lead, ML275, due to the overall profile which included the most improved potency, selectivity window and reduction in viral titer. Probe candidates were routinely assessed in a Eurofins PanLabs (formerly Ricerca) Hit LeadProfiling screen against 67 discrete GPCRs, ion channels and transporters. All assays were performed in duplicate with probe ML275 (19) at a concentration of 10 μM, and >50% inhibition was noted for five targets ( Table 5 ). Inhibition of the human adenosine A 3 receptor and the human platelet activating factor was determined to be 44% and 43%, respectively; however, inhibition of all remaining targets did not exceed 34%. A full list of the targets and percent inhibition by compound 19 
). NT = not tested; NA = not applicable. Data were analyzed using Microsoft Excel 2010.
e Data were an average of outcomes from two separate lots of compound 2. is provided in the Supporting Information. The liability posed by significant inhibition of any given host target depends on a multitude of factors that includes but is not limited to potency, metabolism, and physiological compartmental exposure (e.g., CNS). These results, while not negligible, were considered informational at this stage of development, as pursuit of individual IC 50 values and bioavailability data was costprohibitive and revision of the scaffold architecture was expected prior to finding a suitable tool for in vivo assessment. Nonetheless, the profiling outcome served as a useful alert to potential adverse effects associated with the series that will need to be surveyed as development continues toward an advanced lead candidate.
Mechanism of Action Studies. To gain an understanding of how this quinazolinedione class of compounds was inhibiting RSV, a cell-based, time-of-addition study was initially performed to determine the ability of these compounds to inhibit different stages of a single round of viral replication. The assay was performed by infecting cells with RSV and adding compound at a 10 μM concentration at each of several time points up to 24 h postinfection and then tracking cell viability over the course of the experiment. Compounds 15, 19 , and 46 were evaluated as a panel alongside ribavirin. While ribavirin treatment protected cells from RSV-induced CPE (approximately 100%) for up to 7 h postinfection, indicating that it targets the period of infection during which viral replication is in progress, none of the three quinazolinediones showed dramatic changes in cell viability between 7 and 24 h postinfection, suggesting that these compounds acted at a later stage of the viral life cycle (data not shown). This time-ofaddition profile suggested possible inhibition of the viral RNAdependent RNA-polymerase (RdRp) activity rather than interference with receptor binding and/or membrane fusion. To test this hypothesis experimentally, compounds 15, 19 and 46 were subjected, along with a known literature-described RdRp inhibitor 55, 18 to a plasmid-based RSV minigenome reporter assay that specifically monitored bioactivity of the viral polymerase machinery (Figure 3) . 38 Luciferase reporter interference was tested by comparing the activity of 19 in assays employing recRSV-luciferase or the equivalent measles virus recombinant (recMeV-luciferase), both of which rely on luciferase activity as the assay readout. While recRSV-luciferase was efficiently inhibited, compound 19 was inactive against recMeV-luciferase, excluding direct reporter interference. All four analogs showed a dose-dependent inhibition of reporter expression with active concentrations similar to those observed against live virus, indicating that the compounds blocked RSV RdRp activity.
At this point the exact target with which these compounds interact leading to the observed block of RdRp activity is unknown, but sequencing of RSV-resistant mutant viruses resulting from compound treated cells is currently underway. These studies are expected to pinpoint the location of mutation within the genome that may be responsible for resistance and identify a potential target to investigate further. Attempts to unravel the nature of inhibition are being actively pursued.
■ CONCLUSION
In summary, we have identified a quinazolinedione class of compounds that show promising cellular activity against RSV. While the SAR for this set of quinazolinediones was relatively limited in texture, we have discovered distinct scaffold regions that tolerate structural change and permit tuning of physiochemical properties and whose modification has led to a 7-fold improvement in selectivity over the hit compound 2. Several compounds in the series inhibited a virus-induced cytopathic effect in the submicromolar range without exhibiting significant cellular toxicity, and importantly, these same compounds also significantly reduced viral plaque formation at a concentration of 10 μM. Furthermore, the mechanism of action for a subset of quinazolinedione analogs was explored and demonstrated to block the activity of the viral RNAdependent RNA−polymerase complex which is responsible for RSV genome replication and transcription. These results, combined with the insights from structural modifications of the quinazolinedione scaffold and in vitro ADME data of select analogs, suggest that a favorable pharmacological profile can be tuned to produce a lead antiviral compound suitable for in vivo efficacy assessment against RSV. As such, the current set of compounds will be useful tools in establishing baseline pharmacokinetic parameters and further investigating how these agents interact with the RdRp complex to inhibit viral replication.
■ EXPERIMENTAL SECTION
Chemistry. The purity of all final compounds was >95% and was confirmed by HPLC/MS analysis employing an Agilent 1200 RRL chromatograph with photodiode array UV detection and an Agilent 6224 TOF mass spectrometer. The chromatographic method utilized a Waters Acquity BEH C-18 2.1 × 50 mm, 1.7 μm column; UV detection wavelength = 214 nm; flow rate = 0.4 mL/min; gradient = 5−100% acetonitrile over 3 min with a hold of 0.8 min at 100% acetonitrile; the aqueous mobile phase contained 0.15% ammonium hydroxide (v/v). The mass spectrometer utilized the following parameters: an Agilent multimode source which simultaneously acquires ESI+/APCI+; a reference mass solution consisting of purine and hexakis(1H,1H,3H-tetrafluoropropoxy)phosphazine; and a makeup solvent of 90:10:0.1 MeOH:water:formic acid which was introduced to the LC flow prior to the source to assist ionization. 1 H and 13 C NMR spectra were recorded on a Bruker AM 400 spectrometer (operating at 400 and 101 MHz, respectively) or a Bruker AVIII spectrometer (operating at 500 and 126 MHz, respectively) in CDCl 3 with 0.03% TMS as an internal standard or DMSO-d 6 . The chemical shifts (δ) reported are given in parts per million (ppm) and the coupling constants (J) are in Hertz (Hz) . The spin multiplicities are reported as s = singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublet, hept = heptet, and m = multiplet. Melting points were determined on a Stanford Research Systems OptiMelt apparatus. Compounds were generally prepared according to Scheme 1 and the protocols detailed for compound 19, below, unless otherwise specified.
Step 1. To a solution of 2-aminobenzoic acid 3 (5.00 g, 36.50 mmol) in DMF (45 mL) was added methyl 4-(aminomethyl)benzoate hydrochloride (7.35 g, 36.5 mmol), HATU (15.25 g, 40.10 mmol) and N,N-diisopropylethylamine (18.08 mL, 109 mmol). The reaction mixture was stirred for 16 h at room temperature, then diluted with CH 2 Cl 2 (200 mL) and washed sequentially with 1 M HCl (150 mL), sat. aqueous NaHCO 3 (150 mL) and water (2 × 800 mL). The separated organic extract was dried (MgSO 4 ), filtered, and concentrated under reduced pressure to afford a crude product which was purified by silica gel flash column chromatography (0−60% v/v EtOAc/Hexane), yielding the product, methyl 4-((2-aminobenzamido)methyl)benzoate, as a white solid (5.00 g, 17.59 mmol, 48% yield). Step 2. After stirring a solution of methyl 4-((2-aminobenzamido)-methyl)benzoate (5.00 g, 17.59 mmol) and N,N-diisopropylethylamine (14.53 mL, 88 mmol) in CH 2 Cl 2 (260 mL) for 10 min at room temperature under nitrogen, 1,1′-carbonyldiimidazole (8.55 g, 52.80 mmol) was added, and the reaction mixture was heated 16 h at reflux. The formed precipitate was filtered, dried under vacuum and the desired product, methyl 4-((2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)methyl)benzoate 4, was furnished as a white solid without further purification (4.65 g, 14.99 mmol, 85% yield).
1 H NMR (400 MHz, Step 3. To a solution of methyl 4-((2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)methyl)benzoate 4 (2.60 g, 8.38 mmol) in THF (50 mL) was added 1 M lithium hydroxide (50 mL, 50.3 mmol). The reaction mixture was stirred at 40°C for 1 h, at which point TLC confirmed reaction completion. Then 1 M HCl was cautiously added until the reaction mixture reached pH 2, at which point the product precipitated out of solution. The precipitate was collected by filtration, washed with water (2 × 70 mL), dried under high vacuum to afford the desired product, 4-( (2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl) 15 (s, 2H) .
Step 4. To a solution of 4-((2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)methyl)benzoic acid (1.00 g, 3.38 mmol) in DMF (15 mL) was added 3-methoxypropylamine (0.35 mL, 3.38 mmol), HATU (1.41 g, 3.71 mmol) and N,N-diisopropylethylamine (1.67 mL, 10.13 mmol). The reaction mixture was stirred for 16 h at room temperature, then diluted with CH 2 Cl 2 (90 mL) and washed sequentially with 1 M HCl (60 mL), sat. aqueous NaHCO 3 (60 mL) and water (2 × 180 mL). The organic extract was separated, dried (MgSO 4 ), filtered, and concentrated under reduced pressure to afford a crude product which was purified by silica gel flash column chromatography (0−5% v/v MeOH/CH 2 Cl 2 ) yielding the desired product Step 5. To a solution of 4-((2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)methyl)-N-(3-methoxypropyl)benzamide (0.050 g, 0.14 mmol) in DMF (2 mL) was added 4-isopropylbenzyl bromide (0.028 mL, 0.16 mmol) and potassium carbonate (0.056 g, 0.41 mmol). The resulting reaction mixture was stirred at 40°C for 16 h. The formed residue was dissolved in CH 2 Cl 2 (6 mL) and sequentially washed with 1 M HCl (4 mL), water (3 × 20 mL) and brine (8 mL). The organic layer was separated, dried (MgSO 4 ), filtered, and concentrated under reduced pressure to give a crude product which was purified by silica gel flash column chromatography (0−5% v/v MeOH/CH 2 Cl 2 ) yielding 4- (25) . Isolated as a white solid (35 mg, 62% yield), mp 163−165°C. N-(4-Methoxybutyl)-4-((1-(4-methylbenzyl)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)methyl)benzamide (27) . Isolated as a white solid (21 mg, 57% yield), mp 167−169°C. 1 
4-((1-(2-Bromobenzyl)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)methyl)-N-(3-methoxypropyl)benzamide (8
Step 1: Synthesis of methyl-4-((2-(2-(4-isopropylphenyl)acetamido)benzamido)methyl)benzoate. A catalytic amount of dry DMF (7 drops) was added to a solution of 2-(4-isopropylphenyl)acetic acid (0.891 g, 5.0 mmol) in dry CH 2 Cl 2 (10 mL) under Ar. Oxalyl chloride (2 M in CH 2 Cl 2 , 2.8 mL, 5.6 mmol) was slowly added to the mixture at rt. The reaction mixture was stirred at rt for 30 min and then slowly added to a mixture of methyl-4-((2-aminobenzamido)methyl)benzoate (1.563 g, 5.5 mmol) and pyridine (0.81 mL, 10.0 mmol) in dry CH 2 Cl 2 (10 mL). After stirring at rt for 3 h, the mixture was successively washed with 1 M aq. HCl (2 × 20 mL) and saturated aq. NaHCO 3 (2 × 20 mL) and dried with Na 2 SO 4 to give the title compound (2.072 g, 93%) as a yellow solid. Step 2: Synthesis of 4-((2-(4-isopropylbenzyl)-4-oxoquinazolin-3(4H)-yl)methyl)benzoic acid. A solution of LiOH (0.285 g, 11.9 mmol) in water (12 mL) was added to a solution of methyl-4-((2-(2-(4-isopropylphenyl)acetamido)benzamido)methyl)benzoate (1.056 g, 2.38 mmol) in THF (12 mL). The mixture was stirred at 40°C for 2 h and a second portion of LiOH (0.285 g, 11.9 mmol) was added to the mixture. The mixture was stirred at 40°C for an additional 19 h. At rt, the reaction was quenched with 1 M aq. HCl (25 mL) and the product was extracted with CH 2 Cl 2 (2 × 50 mL). The extracts were dried with Na 2 SO 4 to yield a mixture of 4-((2-(2-(4-isopropylphenyl)acetamido)-benzamido)methyl)benzoic acid and the title compound (0.985 g, 100%) as a pale-yellow solid. It was used in the next step without further purification.
Step 3: Synthesis of 4-((2-(4-isopropylbenzyl)-4-oxoquinazolin-3(4H)-yl)methyl)-N-(3-methoxypropyl)benzamide (52). A mixture of 4-((2-(4-isopropylbenzyl)-4-oxoquinazolin-3(4H)-yl)methyl)benzoic acid (0.985 g, 2.4 mmol) and 4-((2-(2-(4-isopropylphenyl)-acetamido)benzamido)methyl)benzoic acid was dissolved in dry CH 2 Cl 2 (20 mL) and to this solution 3-methoxypropylamine (0.28 mL, 2.75 mmol), DIPEA (0.60 mL, 3.4 mmol), HOBt (0.371 g, 2.75 mmol), and EDCI (0.527 g, 2.75 mmol) were added. The mixture was stirred at rt for 62 h and then concentrated. The remaining residue was purified by flash chromatography (0−10% MeOH/CH 2 Cl 2 ), followed by mass-directed fractionation to give the title compound (0.252 g, 22%) as a white solid. mp 52−55°C. 1 , 5% CO 2 . Following a six day incubation period, the assay plates were equilibrated to room temperature for 30 min. An equal volume (100 μL) of Cell Titer-Glo reagent (Promega Inc.) was added to each well using a MultiFlo Microplate Dispenser (BioTek, Winooski, VT), and the plates were incubated for an additional 10 min at room temperature. At the end of the incubation, luminescence was measured using a multilabel reader (BioTek Synergy 4, Winooski, VT).
Cytotoxicity Assay. Compound cytotoxicity was measured as described elsewhere 36 with some modifications. Briefly, for a dose response study, test compounds were solubilized in DMSO at 20 mM, and then 2-fold serially diluted in DMSO for 8 concentrations.
Compounds diluted in 45 μL of assay media (final DMSO concentration of 0.5%) were added to each well in 96-well microtiter plates in which HEp-2 cells were grown overnight (seeding density of 12,000 cells/well in a volume of 45 μL). The cells were incubated for 5 days unless otherwise noted. To measure cell viability, Cell Titer-Glo reagent (Promega) was added to each well and luminescence was measured using a multilabel reader. Experiments were done at least in triplicate. For CC 50 calculation, relative cell viability compared to the DMSO control cells was plotted using XLfit (IBDS), and CC 50 were calculated using the 4 Parameter Logistic Model or the Sigmoidal Dose−response Model.
Minireplicon Reporter Assay. 38 A recently described firefly luciferase-based RSV minigenome construct under the control of the cellular pol I promoter was used to monitor viral polymerase activity. Cells were cotransfected with this plasmid and plasmids pRSV-L, pRSV-M2-1, pRSV-N, and pRSV-P, respectively. Compounds were added in serial dilutions and luciferase reporter activities determined 40 h post-transfection. If possible, 50 percent effective concentrations (EC 50 values) were calculated based on four-parameter variable-slope nonlinear regression modeling of mean values using the Prism5 (GraphPad) software package. 
